Literature DB >> 19135442

Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.

Jason Lockrow1, Annamalai Prakasam, Peng Huang, Heather Bimonte-Nelson, Kumar Sambamurti, Ann-Charlotte Granholm.   

Abstract

Down syndrome (DS) individuals develop several neuropathological hallmarks seen in Alzheimer's disease, including cognitive decline and the early loss of cholinergic markers in the basal forebrain. These deficits are replicated in the Ts65Dn mouse, which contains a partial trisomy of murine chromosome 16, the orthologous genetic segment to human chromosome 21. Oxidative stress levels are elevated early in DS, and may contribute to the neurodegeneration seen in these individuals. We evaluated oxidative stress in Ts65Dn mice, and assessed the efficacy of long-term antioxidant supplementation on memory and basal forebrain pathology. We report that oxidative stress was elevated in the adult Ts65Dn brain, and that supplementation with the antioxidant vitamin E effectively reduced these markers. Also, Ts65Dn mice receiving vitamin E exhibited improved performance on a spatial working memory task and showed an attenuation of cholinergic neuron pathology in the basal forebrain. This study provides evidence that vitamin E delays onset of cognitive and morphological abnormalities in a mouse model of DS, and may represent a safe and effective treatment early in the progression of DS neuropathology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19135442      PMCID: PMC2704550          DOI: 10.1016/j.expneurol.2008.11.021

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  82 in total

1.  Long-term functional recovery from age-induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain.

Authors:  A Martínez-Serrano; W Fischer; S Söderström; T Ebendal; A Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease.

Authors:  L M Sayre; D A Zelasko; P L Harris; G Perry; R G Salomon; M A Smith
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

3.  Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age-related neurodegeneration.

Authors:  D M Holtzman; Y Li; K Chen; F H Gage; C J Epstein; W C Mobley
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

4.  Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease.

Authors:  F J Jiménez-Jiménez; F de Bustos; J A Molina; J Benito-León; A Tallón-Barranco; T Gasalla; M Ortí-Pareja; F Guillamón; J C Rubio; J Arenas; R Enríquez-de-Salamanca
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome.

Authors:  D M Holtzman; D Santucci; J Kilbridge; J Chua-Couzens; D J Fontana; S E Daniels; R M Johnson; K Chen; Y Sun; E Carlson; E Alleva; C J Epstein; W C Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

7.  Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease.

Authors:  M A Lovell; W D Ehmann; S M Butler; W R Markesbery
Journal:  Neurology       Date:  1995-08       Impact factor: 9.910

8.  A mouse model for Down syndrome exhibits learning and behaviour deficits.

Authors:  R H Reeves; N G Irving; T H Moran; A Wohn; C Kitt; S S Sisodia; C Schmidt; R T Bronson; M T Davisson
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

9.  Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro.

Authors:  J Busciglio; B A Yankner
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

10.  Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury.

Authors:  Y Goodman; M P Mattson
Journal:  Exp Neurol       Date:  1994-07       Impact factor: 5.330

View more
  54 in total

1.  Altered distribution of hippocampal interneurons in the murine Down Syndrome model Ts65Dn.

Authors:  Samuel Hernández-González; Raúl Ballestín; Rosa López-Hidalgo; Javier Gilabert-Juan; José Miguel Blasco-Ibáñez; Carlos Crespo; Juan Nácher; Emilio Varea
Journal:  Neurochem Res       Date:  2014-11-16       Impact factor: 3.996

2.  Overexpression of amyloid-β protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade.

Authors:  Matthew G Bartley; Kristin Marquardt; Danielle Kirchhof; Heather M Wilkins; David Patterson; Daniel A Linseman
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Authors:  Brian E Powers; Ramon Velazquez; Christy M Kelley; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Brain Struct Funct       Date:  2015-12-30       Impact factor: 3.270

4.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model.

Authors:  Jason Lockrow; Heather Boger; Greg Gerhardt; Gary Aston-Jones; David Bachman; Ann-Charlotte Granholm
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice.

Authors:  Christy M Kelley; Brian E Powers; Ramon Velazquez; Jessica A Ash; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2014-04-15       Impact factor: 3.215

Review 6.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

7.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

8.  Designer receptors enhance memory in a mouse model of Down syndrome.

Authors:  Ashley M Fortress; Eric D Hamlett; Elena M Vazey; Gary Aston-Jones; Wayne A Cass; Heather A Boger; Ann-Charlotte E Granholm
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

Review 9.  Molecular basis of pharmacotherapies for cognition in Down syndrome.

Authors:  Katheleen J Gardiner
Journal:  Trends Pharmacol Sci       Date:  2009-12-04       Impact factor: 14.819

10.  Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome.

Authors:  Chelsee A Hewitt; King-Hwa Ling; Tobias D Merson; Ken M Simpson; Matthew E Ritchie; Sarah L King; Melanie A Pritchard; Gordon K Smyth; Tim Thomas; Hamish S Scott; Anne K Voss
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.